Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Int J Oncol ; 42(3): 863-72, 2013 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-23314732

RESUMEN

Intracellular reactive oxygen species (ROS) such as hydrogen peroxide (H(2)O2()) are thought to mediate apoptosis induced by death receptor ligands, including tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). However, the role of H(2)O(2) is controversial, since some evidence suggests that H(2)O(2) acts as an anti-apoptotic factor. Here, we show that exogenously applied H(2)O(2) (30-100 µM) induces cell death in TRAIL-resistant human melanoma cells via intracellular superoxide (O(2)-) generation. H(2)O(2) induced apoptotic or necrotic cell death, depending on the concentration of the oxidant applied; low concentrations of H(2)O(2) preferentially activated the caspase-dependent apoptotic pathway, while high concentrations of H(2)O(2) induced apoptotic and necrotic cell death in a caspase-independent manner. The H(2)O(2)-induced cell death was associated with increased mitochondrial membrane potential collapse and caspase-3/7 activation and ER stress responses including caspase-12 and X-box-binding protein-1 (XBP-1) activation. H(2)O(2) induced intracellular O2- generation even within the mitochondria, while TRAIL did not. The superoxide dismutase mimetic antioxidant MnTBaP [Mn (III) tetrakis (4-benzonic acid) porphyrin chloride] inhibited the H(2)O(2)-induced O(2)- generation, apoptosis and XBP-1 and caspase-12 activation at comparable concentrations. Importantly, H(2)O(2) treatment caused minimal O(2)- generation and apoptosis in normal primary melanocytes. These data show that H(2)O(2) induces endoplasmic reticulum-associated cell death via intracellular O(2)- generation and that malignant melanoma cells are more susceptible than normal cells to this oxidative cell death. The findings suggest that H(2)O(2) has therapeutic potential in the treatment of TRAIL-resistant melanoma.


Asunto(s)
Apoptosis/efectos de los fármacos , Peróxido de Hidrógeno/farmacología , Melanoma/metabolismo , Superóxidos/metabolismo , Ligando Inductor de Apoptosis Relacionado con TNF/metabolismo , Caspasa 12/efectos de los fármacos , Caspasa 12/metabolismo , Caspasa 3/metabolismo , Caspasa 7/metabolismo , Línea Celular Tumoral , Proteínas de Unión al ADN/efectos de los fármacos , Proteínas de Unión al ADN/metabolismo , Estrés del Retículo Endoplásmico , Activación Enzimática , Depuradores de Radicales Libres/farmacología , Humanos , Potencial de la Membrana Mitocondrial , Metaloporfirinas/farmacología , Necrosis , Factores de Transcripción del Factor Regulador X , Factores de Transcripción/efectos de los fármacos , Factores de Transcripción/metabolismo , Proteína 1 de Unión a la X-Box
3.
Dermatology ; 211(2): 159-61, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-16088166

RESUMEN

We report a 63-year-old Japanese man with epilepsy who developed skin eruptions, liver dysfunction, high fever, leukocytosis and atypical lymphocytosis 4 weeks after he had started taking carbamazepine. Titers of human herpesvirus 7 (HHV-7)-specific IgG antibodies were significantly increased and HHV-7 DNA was detected in his serum by polymerase chain reaction. These findings suggested that reactivation of HHV-7 could contribute to the development of drug-induced hypersensitivity syndrome.


Asunto(s)
Carbamazepina/efectos adversos , Hipersensibilidad a las Drogas/diagnóstico , Hipersensibilidad a las Drogas/etiología , Herpesvirus Humano 7/aislamiento & purificación , Infecciones por Roseolovirus/diagnóstico , Carbamazepina/uso terapéutico , ADN Viral/análisis , Epilepsia/diagnóstico , Epilepsia/tratamiento farmacológico , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Pruebas del Parche , Reacción en Cadena de la Polimerasa/métodos , Prednisolona/uso terapéutico , Recurrencia , Medición de Riesgo , Infecciones por Roseolovirus/tratamiento farmacológico , Índice de Severidad de la Enfermedad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA